Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
“What the study means, and what we show, is that location or income should not hinder the use of these [drugs].”
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
Lung cancer advocate Don Stranathan takes on the No. 1 cancer killer.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
November is Lung Cancer Awareness Month.
I wanted to highlight the eye-popping discrepancy in how our federal research dollars are allocated for lung cancer.
I had to get my CT scan two and a half weeks before I met with the oncologist to get the results. That’s a loooooong time to wait!
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
Here’s a list of the approved drugs to treat lung cancer. Click on any of the medications for more info on dosing, side effects and d...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.